Anebulo Pharmaceuticals, Inc. (ANEB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANEB Stock Price Chart Interactive Chart >
ANEB Price/Volume Stats
| Current price | $2.94 | 52-week high | $8.70 |
| Prev. close | $2.98 | 52-week low | $2.75 |
| Day low | $2.75 | Volume | 1,700 |
| Day high | $2.94 | Avg. volume | 5,778 |
| 50-day MA | $5.14 | Dividend yield | N/A |
| 200-day MA | $6.42 | Market Cap | 68.63M |
Anebulo Pharmaceuticals, Inc. (ANEB) Company Bio
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Latest ANEB News From Around the Web
Below are the latest news stories about Anebulo Pharmaceuticals Inc that investors may wish to consider to help them evaluate ANEB as an investment opportunity.
Anebulo Pharmaceuticals GAAP EPS of -$0.05Anebulo Pharmaceuticals press release (ANEB): Q2 GAAP EPS of -$0.05.Cash and cash equivalents were $18M as of December 31, 2021 |
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent UpdatesAUSTIN, Texas--(BUSINESS WIRE)---- $ANEB #ANEB--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2021 and recent updates. Highlights from the fiscal year 2022 second quarter and recent weeks include the following: Initiated a Phase 2 proof-of-concept clinical study t |
We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceAUSTIN, Texas, January 06, 2022--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. Eastern time on the Investors se |
Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public RelationsAUSTIN, Texas, January 06, 2022--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately. |
ANEB Price Returns
| 1-mo | -26.87% |
| 3-mo | -58.00% |
| 6-mo | -53.11% |
| 1-year | -63.25% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...